Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Livongo Health Gained 40.2% in April

By Cory Renauer – May 3, 2020 at 1:56PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Coronavirus fueled isolation is driving up demand for the company's remote monitoring services.

What happened

Shares of Livongo Health (LVGO), a digital healthcare company, soared 40.2% in April, according to data from S&P Global Market Intelligence. The company hasn't reported official first quarter earnings yet, but preliminary figures released last month encouraged the market to drive the stock higher.

So what 

Despite state lockdowns to prevent more COVID-19 outbreaks, Livongo will beat its own forward estimate with topline revenue in a range between $65.5 million and $66.5 million. Previously, the company guided first quarter revenue to a range between $60 million and $62 million. 

Happy guy wearing a vest and tie

Image source: Getty Images.

Unlike a lot of stocks that fell hard in March, Livongo shares stayed relatively buoyant during the coronavirus-fueled market crash. The company's remote monitoring services for people with diabetes, hypertension, and weight management appear more popular than ever.

Now what

An estimated 78% of COVID-19 patients that reach intensive care units have at least one chronic condition. Livongo's services weren't designed to facilitate pandemic-inspired isolation, but they are helping physicians safely manage chronic health conditions during this one.

During the first quarter, Livongo launched services for 620 new clients, which was a mighty big accomplishment for a company that had just 820 clients at the end of 2019. Some of that growth can be attributed to a partnership with DexCom (DXCM 7.05%) that began in January. The partners are working together to allow Livongo Diabetes members a way to sync data from DexCom's popular G6 continuous glucose monitors. 

In addition to signing new clients, individual patients with multiple chronic conditions are making use of multiple services, which could inspire Livongo to raise expectations for the rest of 2020. Management will hold a conference call with analysts to discuss official first quarter numbers on Wednesday, May 6, 2020 after the closing bell.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Livongo Health Inc. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Livongo Health, Inc. Stock Quote
Livongo Health, Inc.
DexCom, Inc. Stock Quote
DexCom, Inc.
$90.97 (7.05%) $5.99

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.